scholarly journals Differential expression of solute carrier family 22 member 3 in cancers of the breast.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Survival Data ◽  
Normal Breast ◽  
Differentially Expressed ◽  
Solute Carrier Family ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Her2 Breast Cancer ◽  
Solute Carrier

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding solute carrier family 22 member 3, SLC22A3, when comparing primary tumors of the breast to the tissue of origin, the normal breast. SLC22A3 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of SLC22A3 in primary tumors of the breast was correlated with overall survival in patients with basal and luminal B subtype breast cancer, but not in patients with luminal A or HER2+ breast cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by molecular subtype. SLC22A3 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

scholarly journals Differential expression of solute carrier family 29 member 4 in cancers of the breast.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Survival Data ◽  
Differentially Expressed Gene ◽  
Normal Breast ◽  
Differentially Expressed ◽  
Solute Carrier Family ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Solute Carrier

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding solute carrier family 29 member 4, SLC29A4, when comparing primary tumors of the breast to the tissue of origin, the normal breast. SLC29A4 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of SLC29A4 in primary tumors of the breast was correlated with overall survival in patients with luminal B subtype cancer and in patients with normal-like subtype cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by PAM50 molecular subtype. SLC29A4 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

scholarly journals Differential expression of solute carrier family 19 member 3 in cancers of the breast.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Survival Data ◽  
Differentially Expressed Gene ◽  
Normal Breast ◽  
Differentially Expressed ◽  
Solute Carrier Family ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Solute Carrier

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding solute carrier family 19 member 3, SLC19A3, when comparing primary tumors of the breast to the tissue of origin, the normal breast. SLC19A3 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of SLC19A3 in primary tumors of the breast was correlated with overall survival in patients with normal-like subtype cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by PAM50 molecular subtype. SLC19A3 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

scholarly journals Differential expression of solute carrier family 7 member 10 in cancers of the breast.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Survival Data ◽  
Differentially Expressed Gene ◽  
Normal Breast ◽  
Differentially Expressed ◽  
Solute Carrier Family ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Solute Carrier

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding solute carrier family 7 member 10, SLC7A10, when comparing primary tumors of the breast to the tissue of origin, the normal breast. SLC7A10 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of SLC7A10 in primary tumors of the breast was correlated with overall survival in patients with basal-like, HER2+ and normal-like subtype cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by PAM50 molecular subtype. SLC7A10 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

scholarly journals Differential expression of solute carrier family 16 member 7 in cancers of the breast.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Survival Data ◽  
Differentially Expressed Gene ◽  
Normal Breast ◽  
Differentially Expressed ◽  
Solute Carrier Family ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Solute Carrier

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding solute carrier family 16 member 7, SLC16A7, when comparing primary tumors of the breast to the tissue of origin, the normal breast. SLC16A7 was also differentially expressed in the tumor cells of patients with triple negative breast cancer. SLC16A7 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of SLC16A7 in primary tumors of the breast was correlated with overall survival in patients with basal-like subtype cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by PAM50 molecular subtype. SLC16A7 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

scholarly journals Differential expression of fibronectin leucine rich transmembrane protein 2 in cancers of the breast.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Survival Data ◽  
Transmembrane Protein ◽  
Differentially Expressed Gene ◽  
Normal Breast ◽  
Differentially Expressed ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Her2 Breast Cancer

Breast cancer affects women at relatively high frequency1. We mined published microarray datasets2,3 to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding fibronectin leucine rich transmembrane protein 2, FLRT2, when comparing primary tumors of the breast to the tissue of origin, the normal breast. FLRT2 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of FLRT2 in primary tumors of the breast was correlated with overall survival in patients with basal and luminal A subtype breast cancer, but not in luminal B or HER2+ breast cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by molecular subtype. FLRT2 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

scholarly journals Differential expression of leiomodin 1 in cancers of the breast.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Survival Data ◽  
Molecular Subtype ◽  
Differentially Expressed Gene ◽  
Normal Breast ◽  
Differentially Expressed ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Her2 Breast Cancer

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding leiomodin 1, LMOD1, when comparing primary tumors of the breast to the tissue of origin, the normal breast. LMOD1 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of LMOD1 in primary tumors of the breast was correlated with recurrence-free survival in patients with basal subtype or HER2+ breast cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by molecular subtype. LMOD1 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

scholarly journals Differential expression of G protein subunit gamma 11 in cancers of the breast.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
G Protein ◽  
Survival Data ◽  
Normal Breast ◽  
Differentially Expressed ◽  
Protein Subunit ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Her2 Breast Cancer

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding G protein subunit gamma 11, GNG11, when comparing primary tumors of the breast to the tissue of origin, the normal breast. GNG11 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of GNG11 in primary tumors of the breast was correlated with post-progression survival in patients with luminal A subtype or HER2+ breast cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by molecular subtype. GNG11 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

scholarly journals Differential expression of LIM domain binding 2 in cancers of the breast.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Survival Data ◽  
Molecular Subtype ◽  
Differentially Expressed Gene ◽  
Normal Breast ◽  
Differentially Expressed ◽  
Lim Domain ◽  
Significant Differential Expression ◽  
Primary Tumors

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding LIM domain binding 2, LDB2, when comparing primary tumors of the breast to the tissue of origin, the normal breast. LDB2 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of LDB2 in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal A subtype cancers, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by molecular subtype. LDB2 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

scholarly journals Differential expression of Rho GTPase-activating protein 20 in cancers of the breast.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Survival Data ◽  
Rho Gtpase ◽  
Differentially Expressed Gene ◽  
Normal Breast ◽  
Differentially Expressed ◽  
Gtpase Activating Protein ◽  
Significant Differential Expression ◽  
Primary Tumors

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding Rho GTPase-activating protein 20, ARHGAP20, when comparing primary tumors of the breast to the tissue of origin, the normal breast. ARHGAP20 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of ARHGAP20 in primary tumors of the breast was correlated with overall survival in patients with HER2+ subtype cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by PAM50 molecular subtype. ARHGAP20 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

scholarly journals Differential expression of CKS2 in cancers of the breast.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Survival Data ◽  
Normal Breast ◽  
Differentially Expressed ◽  
Regulatory Subunit ◽  
Luminal A ◽  
Gene Encoding ◽  
Significant Differential Expression ◽  
Primary Tumors

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding the CDC28 protein kinase regulatory subunit 2, CKS2, when comparing primary tumors of the breast to the tissue of origin, the normal breast. CKS2 was also differentially expressed in the tumor cells of patients with triple negative breast cancer. CKS2 mRNA was present at significantly higher quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of CKS2 in primary tumors of the breast was correlated with overall survival in patients with basal and luminal A subtype cancer, but in a contrary manner. CKS2 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

Sign in / Sign up

Export Citation Format

Share Document